Magnesium aspartate

Magnesium aspartate, the chelated magnesium salt of aspartic acid, it is a mineral supplement.[1]

Magnesium aspartate
Clinical data
AHFS/Drugs.comConsumer Drug Information
ATC code
Identifiers
IUPAC name
  • magnesium (2S)-2-amino-4-hydroxy-4-oxobutanoate
CAS Number
PubChem CID
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.038.806
Chemical and physical data
FormulaC8H12MgN2O8
Molar mass288.495 g·mol−1
 NY (what is this?)  (verify)

Chemical action

This form of magnesium supplementation has increased bioavailability compared to magnesium oxide and magnesium citrate. There were some promising clinical trials conducted in the 1960s that found a combination of magnesium and potassium aspartates had a positive effect on fatigue and they reduced muscle hyper-excitability.[2]

In its evaluation in 2005, the AFC Panel concluded that in humans the bioavailability of magnesium from magnesium L-aspartate was similar to that from other organic magnesium salts and the more soluble inorganic magnesium salts.[3] Overall, it was concluded that organic salts of magnesium have the greatest water solubility and demonstrate a greater oral absorption and bioavailability compared to less soluble magnesium preparations such as magnesium oxide, magnesium hydroxide, magnesium carbonate and magnesium sulphate.[4]

Dosage
Institute of Medicine (IOM) recommendations for supplemental magnesium[5]
Age Male Female Pregnancy Lactation
Birth to 6 months 30 mg* 30 mg*
7–12 months 75 mg* 75 mg*
1–3 years 80 mg 80 mg
4–8 years 130 mg 130 mg
9–13 years 240 mg 240 mg
14–18 years 410 mg 360 mg 400 mg 360 mg
19–30 years 400 mg 310 mg 350 mg 310 mg
31–50 years 420 mg 320 mg 360 mg 320 mg
51+ years 420 mg 320 mg
  • Adequate Intake (AI)

Magnesium-L-aspartate 1230 mg (magnesium 122 mg) up to 3 times/day Dosage adjustment in renal impairment: Patients with severe kidney failure should not receive magnesium due to toxicity from accumulation.[6]

Magnesium supplements and other magnesium containing products, such as antacids, can bind with prescription medicines, reducing their effectiveness.[7]

Safety

When considering aspartate sources individually, the levels of exposure estimated in this opinion amount up to 6 g/day for calcium aspartate (equivalent to 100 mg/kg bw/day for a 60 kg individual), 5.8 g/day for magnesium aspartate (equivalent to 97 mg/kg bw/day), 4 g/day for potassium aspartate (equivalent to 67 mg/kg bw/day), 0.05 g/day for zinc aspartate (0.8 mg/kg bw/day) and 0.008 g/day for copper aspartate (0.1 mg/kg bw/day). These values are all below those reported to induce amino acid imbalance in intervention trials (6.3 g aspartate/day) and they are, respectively, 7, 7.2, 10.5, 875 and 7000 times lower than the NOAEL for aspartate identified from a 90-day rat study. Based on these margins of safety, the Panel concludes that the use of zinc and copper aspartate, as sources of zinc and copper at the proposed use levels, are not of safety concern but that the use of calcium, magnesium and potassium aspartate could be of safety concern because the margins of safety are considered too low. The Panel notes that if all sources would be used simultaneously, combined exposure will be 16 g/day (equivalent to 267 mg/kg bw/day), which is above the reported amounts inducing amino acid imbalance in intervention trials (6.3 g/day). Furthermore, this value is only 3 times lower than the NOAEL from the rat study and due to the low margin of safety the Panel considers this of safety concern. The Panel estimates that the exposure to aspartate from these food supplements should be added to the aspartate exposure arising from the diet.

Based on US data, estimates of the mean exposure to aspartic acid arising from the diet are 4.1 g/day (children 1-3 year old) to 9.3 g/day (males 19-30 year old) and at the 95th percentile 6.6 g/day (children 4-8 year old) to 12.9 g/day (males 19-50 year old). Under these conditions, estimates of maximum daily exposure to aspartate ions from the diet (13 g/day) and from calcium or magnesium aspartate supplements would be approximately 19 g/day6, and from potassium aspartate would be 17 g/day.[8] Aspartate exposure estimates from zinc or copper supplementation would not significantly change aspartate exposure from the diet.

Taken individually these levels of exposure are lower than those reported to induce amino acid imbalance in intervention trials, when aspartate exposure from the diet is also taken into consideration (19.3 g/day).[9] However, when considering the potential total intake of aspartic ions arising from the diet and from a potential multi-mineral combination of all food supplements the exposure could add up to 29 g/day.[10] In line with the SCF concerns, the Panel considers that the use of L-amino acids in food supplements should not give rise to a nutritional imbalance of the amino acids. Thus the Panel concludes that under these conditions aspartate ion exposure from a multi-mineral combination of this type could be of safety concern.[4]

References
  1. "Magnesium L-aspartate". PubChem. Retrieved 31 December 2015.
  2. Ianna M. "Understanding Different Types of Magnesium". drnibber.com. Retrieved 31 December 2015.
  3. "Opinion of the Scientific Panel on Food Additives, Flavourings, Processing Aids and Materials in Contact with Foods on a request from the Commission related to Magnesium Aspartate as a mineral substance used as a source of magnesium in dietary foods for special medical purposes". The EFSA Journal. 167: 1–6. 2005.
  4. "Magnesium aspartate, potassium aspartate, magnesium potassium aspartate, calcium aspartate, zinc aspartate, and copper aspartate as sources for magnesium, potassium, calcium, zinc, and copper added for nutritional purposes to food supplements" (PDF). The EFSA Journal. 883: 1–23. 2008. Retrieved 31 December 2015 – via efsa.europa.eu.
  5. "Magnesium Fact Sheet for Health Professionals". NIH. Retrieved 31 December 2015.
  6. "Magnesium L-aspartate Hydrochloride". Baltimore Washington Health Center. Univ. of Maryland. Retrieved 31 December 2015.
  7. "magnesium aspartate HCl". WebMD. Retrieved 31 December 2015.
  8. "Technical dossier on DL-magnesium-aspartate-tetrahydrate. February 2005g. Submitted by Gradiens Ltd. Budapest, Hungary."
  9. "Technical dossier on magnesium L-aspartate. May 2005h. Submitted by Health Food Manufacturer’s Association. Surrey, England."
  10. "Technical dossier on magnesium L-aspartat e. June 2005i. Submitted by Kiwi Farm b.v. Katwijk, Nederland."
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.